Samyang Biopharm
Seoul, South Korea
Hybrid — also manufactures internal programs
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (2)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (1)
Quick Facts: Samyang Biopharm
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- Seoul, South Korea
- Website
- https://www.samyangbiopharm.com/
- Modalities
- Sterile Injectables, Cytotoxics, Lyophilization, Oncology Products
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Samyang Biopharm
Samyang Biopharm makes its own pharmaceutical products and also offers contract development and manufacturing services. Capabilities: Sterile Injectables, Cytotoxics, Lyophilization, Oncology Products. 1 manufacturing site registered with the U.S. FDA and Health Canada. Website: https://www.samyangbiopharm.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source:
public careers pages
· Checked Oct 30, 2026
Company Signals 2 articles
Company announcements, not verified evidence. They do not change any score.
Samyang Biopharm, CrossPoint team up to develop tumor-targeted gene therapies - Korea Biomedical Review
Samyang Biopharm, CrossPoint team up to develop tumor-targeted gene therapies Korea Biomedical Review
Samyang Biopharm, Crosspoint Therapeutics team up to develop next-generation targeted gene therapy - 헤럴드경제
Samyang Biopharm, Crosspoint Therapeutics team up to develop next-generation targeted gene therapy 헤럴드경제
Frequently Asked Questions About Samyang Biopharm
Does Samyang Biopharm have a CDMO Signal Score?
Not yet. Samyang Biopharm is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Samyang Biopharm for a manufacturing program?
Use the free AI matchmaker to compare Samyang Biopharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
Gensenta (formerly Mustafa Nevzat)
Istanbul, Turkey
Sterile Injectables, Lyophilization, Oral Solid Dose, Oncology Products, Small Molecule API
Hikma (Contract Manufacturing)
United States
Oral Solid Dose, Oral Liquids, Inhalation & Nasal, Sterile Injectables, Lyophilization, Prefilled Syringes, Cytotoxics
medac
Wedel, Schleswig-Holstein, Germany
Sterile Injectables, Lyophilization, High-Potency APIs, Cytotoxics, Clinical Trial Manufacturing
Exela Pharma Sciences
Lenoir, North Carolina, United States
Sterile Injectables, Lyophilization, IV Bags, Prefilled Syringes
Gufic Biosciences
India
Sterile Injectables, Lyophilization
Compare Samyang Biopharm with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.